Yuhan Corporation

“Provide the best Products for the people”

In 1926, Dr. Ilhan New founded Yuhan Corporation with the belief that only healthy people could reclaim their sovereignty and he sought to solve widespread public health problems. Today, Yuhan continues to grow as a global company, with the wellness of people as our first priority.

Research and development (R&D) strategies at Yuhan Research Institute (YRI) are driven, first and foremost, by patient need. This patient-focused approach leads YRI to concentrate on three critical areas of unmet medical need: cardiovascular/metabolic diseases; inflammatory/immune disorders; and oncology. YRI is dedicated to bringing superior treatment options to millions of patients worldwide. To create R&D value, YRI have succeeded in meeting the strategic goal of out-licensing four drugs, amounting to U$ 3 billion until July 2019.

Completed in 2006, our Ochang General Formulations Plant is highly automated and in full compliance with PIC/s GMP. It features scalable and flexible production lines and advanced logistics systems, giving Yuhan the capability to bring high-quality medicines to market and to patients efficiently.

Yuhan is prepared to take the lead toward a future filled with new pharmaceutical discoveries and continuing growth. Yuhan will always be with you, our customers and partners, to create a healthier and more prosperous society.